Skip to main content
Premium Trial:

Request an Annual Quote

Ingenuity Licenses Pathway Analysis Software to Genizon BioSciences ...

NEW YORK, Oct. 25 (GenomeWeb News) - Ingenuity Systems will license its pathway analysis software to Genizon BioSciences, the companies announced today.

 

Under the agreement, Genizon will apply Ingenuity Pathways Analysis 3.0 to its lead programs studying Crohn's disease, psoriasis, asthma, baldness, and schizophrenia.

 

Genizon, formerly called Galileo Genomics, conducts whole genome-association studies on common diseases to identify major genes and their interactions.

 

The Ingenuity Pathway Analysis product enables scientists to create and analyze custom networks for targets, biomarkers, disease areas, and processes.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.